智通财经APP讯,复星医药(02196)发布公告,近日,公司控股子公司重庆药友制药有限责任公司就氟比洛芬酯注射液的药品注册申请获国家药品监督管理局批准,本次获批适应症为用于术后及癌症的镇痛。
该药品为集团自主研发的化学药品。截至2026年3月,集团现阶段针对该药品的累计研发投入约为人民币0.34亿元(未经审计)。
根据IQVIA CHPA最新数据,2025年,氟比洛芬酯注射液于中国境内(不包括港澳台地区)的销售额约为人民币11.58亿元。
智通财经APP讯,复星医药(02196)发布公告,近日,公司控股子公司重庆药友制药有限责任公司就氟比洛芬酯注射液的药品注册申请获国家药品监督管理局批准,本次获批适应症为用于术后及癌症的镇痛。
该药品为集团自主研发的化学药品。截至2026年3月,集团现阶段针对该药品的累计研发投入约为人民币0.34亿元(未经审计)。
根据IQVIA CHPA最新数据,2025年,氟比洛芬酯注射液于中国境内(不包括港澳台地区)的销售额约为人民币11.58亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.